GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk.  | GSK is ...

GSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid what a spokesperson said is “decreasing demand” for egg-based flu shots.

GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at risk. The decision reflects declining demand for traditional egg-based flu ...

By Puyaan Singh and Bhanvi Satija Sept 11 (Reuters) - GSK said on Friday it will be shutting down a vaccine factory in ...

GSK (LSE:GSK) agreed to acquire Chimagen's trispecific T cell-engager candidate for multiple myeloma, expanding its blood cancer research portfolio. The drug asset is described by the parties as a ...

While the United Kingdom feted President Trump in his second state visit, GSK said Wednesday it will spend $30 billion over the next five years to build new manufacturing and research facilities ...

GSK plc (NYSE:GSK) on Wednesday announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years. The update includes ...

GSK agrees to acquire a trispecific T cell engager for multiple myeloma from Chimagen Biosciences, while Sanofi is offloading 20 mature medicines and three manufacturing sites to Cheplapharm. GSK and ...

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bora Pharmaceuticals Co., Ltd. (“Bora”; TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, and GSK (LSE/NYSE: GSK) have signed a ...

GSK plc GSK has unveiled a $30 billion investment plan in research and development (R&D) and supply chain infrastructure in the United States, which will be executed over the next five years. GSK’s ...